Replies to post #220031 on Biotech Values

[DaveAu]

For insertions, the donor portion is still delivered by a vector even when the zinc fingers are delivered by electroporation.

SGMO has been editing T cells, without the use of a virus, for years. Much, is not all, of HIV work was down using electroporation of isolated T cells. So this is not new or revolutionary.

[DewDiligence]

SGMO acquires TCXL.PA for €2.58/sh cash—a 174% premium to Friday’s close:

https://investor.sangamo.com/press-releases/detail/414

The nominal deal value is €72M ($84M).